epidiolex

Medical marijuana has been used to treat epilepsy in patients for years, but so far, it's efficacy and safety hasn't been supported by a regulatory green light from the Food and Drug Administration (FDA). Based on recently reported results for Epidiolex, a cannabidiol epilepsy medicine, that...

This time next year, an investigational drug hailed as a breakthrough in the science of cannabidiol could be prescribed to children suffering from treatment-resistant epilepsy. The prospect of its success, however, has caused some unease in the American hemp industry. London-based GW...

The marijuana market is growing rapidly and that's creating a lot of interest in owning marijuana stocks. However, investors need to pick what marijuana stocks to buy carefully. There's likely to be more losers in this industry than winners, and it could be a long time before any of these...

A lot of progress is being made on understanding how marijuana's chemical cannabinoids can be used as medicine, and among the most intriguing of these cannabinoids is cannabidiol, or CBD. It's one of at least 113 active cannabinoids found in marijuana, it's not responsible for marijuana's...

Support of marijuana legalization is at an all-time high. States across the country have legalized marijuana, either for medical use, recreational use, or both. You might think that every marijuana stock would benefit from these trends. But that's not the case. One company with a cannabinoid...

British biotech company GW Pharmaceuticals announced positive results on its latest Phase 3 clinical trial for its drug Epidiolex. The drug is cannabidiol-based and is used to treat children with Lennox-Gastaut syndrome, a rare form of childhood epilepsy. The results from the test were very...

British biotech company GW Pharmaceuticals announced positive results on its latest Phase 3 clinical trial for its drug Epidiolex. The drug is cannabidiol-based and is used to treat children with Lennox-Gastaut syndrome, a rare form of childhood epilepsy. The results from the test were very...

An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain's GW Pharmaceuticals to a record high on Monday. GW, which was founded in 1998 to capitalize on the medical benefits of cannabis, said...

An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain's GW Pharmaceuticals to a record high on Monday. GW, which was founded in 1998 to capitalize on the medical benefits of cannabis, said...

What: After reporting that its marijuana-derived drug Epidiolex reduced the number of monthly seizures in patients with Lennox-Gastaut syndrome, GW Pharmaceuticals Plc shares jumped 10.6% last month, according to S&P Global Market Intelligence. So what: Earlier this year, a phase 3 trial in...

What: After reporting that its marijuana-derived drug Epidiolex reduced the number of monthly seizures in patients with Lennox-Gastaut syndrome, GW Pharmaceuticals Plc shares jumped 10.6% last month, according to S&P Global Market Intelligence. So what: Earlier this year, a phase 3 trial in...

An oil derived from marijuana plants proved effective in a rare form of epilepsy that afflicts 30,000 Americans, its maker said this morning. GW Pharmaceuticals, a London-based company, is developing a drug called Epidiolex, a pharmaceutical-grade form of cannabidiol (CBD), an oil found in...

An oil derived from marijuana plants proved effective in a rare form of epilepsy that afflicts 30,000 Americans, its maker said this morning. GW Pharmaceuticals, a London-based company, is developing a drug called Epidiolex, a pharmaceutical-grade form of cannabidiol (CBD), an oil found in...

Children afflicted with Dravet Syndrome, a rare form of epilepsy, have been effectively treated with a cannabis-based drug, Epidiolex, containing cannabinoids, the GW Pharmaceuticals announced Monday. Investors snapped up shares of the little-known firm, effectively doubling the company's market...

An experimental cannabis-based drug has successfully treated children with a rare form of severe epilepsy in a keenly anticipated clinical trial, more than doubling the value of its maker GW Pharmaceuticals. The study of GW's Epidiolex in Dravet syndrome is the first of four final-stage Phase...